AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2542197
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy combined with misonidazole (400 mg/m2 2‐4 hr prior to RT daily for 5‐6 weeks)
Trial: 29733400
Drug: ILO once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ILO once monthly (group B)
Trial: 25638597
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day whey protein-supplemented beverage
Trial: 21040143
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (Gamunex)
Trial: 16550750
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (any approved phosphate binder)
Trial: 8783327
Drug: NSAID‐morphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID‐morphine treatment
Trial: 1479003
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Trial: 1479003
Drug: 1.87 mg
RxNorm normalized name: proline 1.87 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.87 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Trial: 29671368
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin E
Trial: 29671368
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin C
Trial: 29671368
Drug: Topical human
RxNorm normalized name: thrombin topical human topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) alone
Trial: 24521245
Drug: Lixisenatide (LIXI)
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lixisenatide (LIXI) 20 µg
Trial: 22468806
Drug: Pemetrexed 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 1,800 mg/m2 plus cyclophosphamide 600 mg/m2
Trial: 22468806
Drug: Pemetrexed 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 600 mg/m2 plus cyclophosphamide 600 mg/m2
Trial: 15655124
Drug: Lisinopril with
RxNorm normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril with or without hydrochlorothiazide, or nifedipine or an angiotensin receptor blocker for uncontrolled hypertensive subjects
Trial: 15655124
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no treatment) for normotensive and treated hypertensive subjects
Trial: 7796586
Drug: Oral monophasic
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral monophasic contraceptive (ethinylestradiol 20 micrograms + desogestrel 0.150 mg)
Trial: 2356085
Drug: Prophylactic diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic diflunisal (two tablets immediately at the conclusion of the visit, then four tablets to be taken in the schedule of one every 8 to 12 hours for pain if needed)
Trial: 2356085
Drug: On-demand diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-demand diflunisal (same dosage schedule; pills to be taken only if needed)
Trial: 26689281
Drug: Pre-quit nicotine
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-quit nicotine patch treatment (two weeks of patch treatment prior to a quit day, followed by 10 weeks post-quit treatment)
Trial: 26689281
Drug: Standard patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard patch treatment (10 weeks of patch starting from a designated quit day)
Trial: 21380937
Drug: Naltrexone (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (4.5 mg daily)
Trial: 15059710
Drug: DHA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (400 mg/d)
Trial: 17142642
Drug: Aquatic physical
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic physical therapy for 6 weeks
Trial: 17142642
Drug: No aquatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aquatic physical therapy (control)
Trial: 11026748
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Ginkgo biloba
Trial: 11026748
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg Ginkgo biloba
Trial: 11026748
Drug: 360 mg
RxNorm normalized name: aspirin 360 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg Ginkgo biloba
Trial: 9062542
Drug: Low-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose beta-carotene (0.5 mg/d) for days 1-60
Trial: 3000176
Drug: Sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbinil (250 mg daily for 6 weeks)
Trial: 22327755
Drug: Standard hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hospital treatment (n=21)
Trial: 20189552
Drug: Informative adjective-noun
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informative adjective-noun phrases (e.g. blue car)
Trial: 15653967
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) exposure
Trial: 8953203
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment (sulfonylurea)
Trial: 1672588
Drug: Intermittent medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent medication (given only when the patient shows early signs of relapse)
Trial: 1672588
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of maintenance medication
Trial: 1672588
Drug: Intermittent medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent medication
Trial: 31281931
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics used prior to culture within 30 days
Trial: 25651842
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy (ART) initiation
Trial: 22908169
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg piperacillin
Trial: 22908169
Drug: 3,000 mg
RxNorm normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 mg piperacillin
Trial: 22908169
Drug: High-dose short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose short-term infusions (6 g every 8 h)
Trial: 22908169
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous infusions (6 g/day)
Trial: 19126633
Drug: Immediate intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate intervention (start of cancer treatment)
Trial: 19126633
Drug: Delayed intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed intervention (8 weeks after starting treatment)
Trial: 17407391
Drug: Subcutaneous glatiramer
RxNorm normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous glatiramer acetate (SC GA)
Trial: 17407391
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a (IM IFNbeta‐1a)
Trial: 17407391
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta-1a (SC IFNbeta‐1a)
Trial: 17407391
Drug: Subcutaneous interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous interferon beta-1b (SC IFNbeta‐1b)
Trial: 15357164
Drug: Povidone-iodine ointment
RxNorm normalized name: Povidone-Iodine Ointment
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine ointment and gauze dressings
Trial: 11167352
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg cetirizine
Trial: 11167352
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg levocetirizine
Trial: 11167352
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ucb 28557
Trial: 7833105
Drug: CEV (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEV (cyclophosphamide 1000 mg/m2 i.v., epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks)
Trial: 7833105
Drug: PE (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks)
Trial: 28051270
Drug: Retroperitoneal laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal laparoscopic partial dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group A)
Trial: 28051270
Drug: Retroperitoneal laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal laparoscopic complete dissection of adipose renal capsule plus ligation of renal pedicle lymphatic vessels (Group B)
Trial: 26149996
Drug: Lopinavir (LPV)
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lopinavir (LPV) treatment during pregnancy
Trial: 21348538
Drug: Saxagliptin 10
RxNorm normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 10 mg (Onglyza™)
Trial: 21348538
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg (2.5 mg orally once daily)
Trial: 16950285
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of farm exposure and CD14-159TT genotype
Trial: 7827905
Drug: Preoperative mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative mechanical bowel preparation (group 1)
Trial: 7827905
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (group 2)
Trial: 3168339
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride (10 mmol in 100 ml isotonic sodium chloride)
Trial: 29026903
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g freeze dried blueberry powder (WBB)
Trial: 22088858
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day ezetimibe/simvastatin combination therapy
Trial: 16355341
Drug: Atazanavir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir, 400 mg once daily plus efavirenz placebo
Trial: 16355341
Drug: Efavirenz, 600
RxNorm normalized name: Efavirenz, 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz, 600 mg once daily plus atazanavir placebo
Trial: 10739509
Drug: Continuous-combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous-combined hormone replacement therapy (conjugated equine estrogens 0.625 mg/d with medroxyprogesterone acetate 2.5 mg/d)
Trial: 31001264
Drug: SjCTPI bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SjCTPI bovine vaccine (prime-boost regimen)
Trial: 31001264
Drug: Human mass
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human mass chemotherapy (praziquantel)
Trial: 31001264
Drug: SjCTPI bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SjCTPI bovine vaccine
Trial: 25538277
Drug: H3N2c cell‐culture‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2c cell‐culture‐derived vaccine with MF59 adjuvant
Trial: 25538277
Drug: H3N2c cell‐culture‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2c cell‐culture‐derived vaccine without MF59 adjuvant
Trial: 25538277
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg + 0.25 mL MF59
Trial: 25538277
Drug: MF59‐adjuvanted H3N2c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59‐adjuvanted H3N2c vaccines
Trial: 22111718
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose budesonide (0.5 mg nightly)
Trial: 22111718
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose budesonide (1 mg twice daily for 7 days during respiratory illness)
Trial: 18953855
Drug: Partial neuromuscular
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial neuromuscular relaxation maintained at train of four stimulation (TOF)=3 by continuous vencronium infusion
Trial: 16409339
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg morphine
Trial: 22912697
Drug: Chloroquine monotherapy
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine monotherapy
Trial: 1515386
Drug: 17.5 ml
RxNorm normalized name: 17.5 ML Fusilev 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 ml mepivacaine
Trial: 1515386
Drug: 17.5 ml
RxNorm normalized name: 17.5 ML Fusilev 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 ml bupivacaine
Trial: 30498351
Drug: 3-monthly paliperidone
RxNorm normalized name: paliperidone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-monthly paliperidone palmitate (PP3M)
Trial: 30498351
Drug: once-monthly paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once-monthly paliperidone palmitate (PP1M)
Trial: 26845640
Drug: Multifaceted peer-group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted peer-group based intervention including FP communication skills training, antibiotic prescribing agreements, and quarterly feedback figures.
Trial: 22152974
Drug: Intensified N-terminal
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified N-terminal brain natriuretic peptide-guided HF therapy
Trial: 3302110
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg/day
Trial: 3302110
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg/day
Trial: 17453362
Drug: Dose-escalated chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated chemotherapy (de FEC)
Trial: 15610835
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 1, men)
Trial: 15610835
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 2, women)
Trial: 15610835
Drug: Fentanyl 1.5
RxNorm normalized name: fentanyl 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.5 microg/kg and thiopental 2 mg/kg (Group 3, women)
Trial: 9701719
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 50 microgram TRH administered intravenously at 22.00, 23.00, 24.00, and 01.00 h
Trial: 31585343
Drug: 10-week internet-delivered
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-week internet-delivered exposure therapy
Trial: 25441960
Drug: Tablet computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer usage
Trial: 23550808
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dehydroepiandrosterone (DHEA) added to EE/DRSP COC
Trial: 12600797
Drug: ibuprofen 400mg
RxNorm normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 400mg
Trial: 10929920
Drug: Zafirlukast 10
RxNorm normalized name: zafirlukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 10 mg BID
Trial: 10929920
Drug: Zafirlukast 5
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast 5 mg BID
Trial: 11101185
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg BID
Trial: 10929920
Drug: Zafirlukast 40
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast 40 mg BID
Trial: 8644030
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (nifedipine, verapamil, diltiazem)
Trial: 25899875
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment efficacy
Trial: 8644030
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists treatment
Trial: 3901672
Drug: mianserin 30
RxNorm normalized name: mianserin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 30 mg
Trial: 3901672
Drug: clonidine 0.150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clonidine 0.150 mg
Trial: 30836809
Drug: Low-frequency airborne
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency airborne ultrasound therapy (Glybetac)
Trial: 18835735
Drug: Oral 17beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 17beta‐oestradiol valerate 2mg twice daily
Trial: 14745340
Drug: Comparer antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparer antibiotics (amoxicillin-clavulanic acid, amoxicillin, ceftriaxone, ceftriaxone plus cefuroxime +/- erythromycin)
Trial: 14745340
Drug: Comparer antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparer antibiotics
Trial: 9696721
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g/day)
Trial: 9696721
Drug: glycine (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycine (13 g/day; placebo)
Trial: 16229022
Drug: Qigong treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong treatment group (n = 32)
Trial: 15526246
Drug: Amiodarone 400
RxNorm normalized name: amiodarone 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 400 mg daily plus irbesartan 300 mg daily
Trial: 15526246
Drug: Amiodarone 400
RxNorm normalized name: amiodarone 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 400 mg daily plus irbesartan 150 mg daily
Trial: 15526246
Drug: Amiodarone 400
RxNorm normalized name: amiodarone 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 400 mg daily
Trial: 11139948
Drug: Pilsicainide (PLS)
RxNorm normalized name: ethanol
DrugBank: Pilsicainide (DB12712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilsicainide (PLS) 100-150 mg single oral dose
Trial: 11139948
Drug: Disopyramide (DISO)
DrugBank: Disopyramide (DB00280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disopyramide (DISO) 2 mg/kg infusion (maximum dose = 100 mg)
Trial: 9313630
Drug: Sulodexide (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (administered IM for ten days and orally for fifty days)
Trial: 9313630
Drug: Calcium Heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Heparin (subcutaneous for sixty days)
Trial: 7039840
Drug: Cinoxacin 250
RxNorm normalized name: cinoxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinoxacin 250 mg, four times a day
Trial: 7039840
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg, four times a day
Trial: 30781485
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of flavanol‐rich cocoa powder ingested with a diabetic‐suitable breakfast